The US Food and Drug Administration (FDA) has approved the Tidepool “artificial pancreas” app. The prescription-only software connects continuous glucose monitors (CGMs) and insulin pumps to automate insulin delivery and blood sugar management in patients with Type I diabetes. The app will work with certain devices and provide a single place to find blood sugar and insulin dosage data.
According to Andrea Park, “Tidepool hasn't yet announced which devices will be available for integration with the app at its launch but said in this week's release that it's in the process of finalizing agreements with some makers of CGMs and insulin pumps. The nonprofit also has ongoing development partnerships with Dexcom and other unnamed devicemakers to bring their current and future products into the Loop.”
To read more, click here.
(Source: Fierce Biotech, January 25th, 2023)
